MIRM
Mirum Pharmaceuticals Inc
82.90$
-1.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 59.7% | 59.9% | 59.7% | 55.7% | 57.9% | 58.6% | 59.5% | 62.5% | 67.6% | 65.2% | 63.9% | 60.9% | |
| 46.6% | 44.3% | 46.5% | 35.3% | 33.4% | 33.2% | 30.7% | 31.4% | 35.9% | 35.2% | 36.5% | 31.6% | |
| 47.0% | 44.3% | 46.5% | 42.1% | 42.6% | 41.8% | 40.2% | 42.0% | 47.8% | 45.5% | 43.4% | 41.9% | |
| 7.4% | 10.5% | 8.4% | 9.1% | 10.3% | 11.7% | 13.9% | 14.7% | 13.6% | 14.6% | 14.9% | 13.9% | |
| 3.4% | 3.5% | 3.3% | 3.1% | 3.2% | 3.3% | 3.2% | 3.2% | 3.1% | 3.0% | 2.9% | 2.5% | |
| 0.3% | – | – | – | – | – | – | – | – | – | – | – | |
| 39.7% | 39.1% | 39.5% | 39.6% | 38.3% | 37.2% | 35.3% | 32.8% | 29.5% | 31.0% | 28.5% | 23.7% | |
| 58.6% | 61.5% | 64.0% | 65.3% | 65.3% | 66.4% | 66.2% | 64.8% | 62.8% | 62.7% | 72.8% | 101.0% | |
| 11.5% | 13.5% | 16.2% | 17.0% | 17.3% | 18.9% | 18.5% | 19.9% | 20.4% | 24.4% | 30.6% | 21.3% | |
| 0.2% | 0.2% | 0.1% | 0.2% | 0.2% | 0.3% | 0.2% | 0.3% | 0.3% | 0.3% | 0.3% | – | |
| 1.1% | 1.1% | 2.5% | 1.5% | 1.4% | 2.2% | 1.7% | 2.4% | 1.5% | 1.1% | 6.7% | 2.2% | |
| 47.0% | 47.4% | 47.1% | 46.5% | 46.1% | 45.9% | 44.7% | 42.6% | 39.4% | 36.8% | 34.8% | 71.8% | |
| 41.4% | 38.5% | 36.0% | 34.7% | 34.7% | 33.6% | 33.8% | 35.2% | 37.2% | 37.3% | 27.2% | -1.0% | |
| -80.0% | -86.0% | -89.2% | -91.7% | -92.9% | -96.0% | -95.5% | -91.6% | -84.3% | -79.2% | -163.6% | -145.9% | |
| 6.3% | 7.2% | 7.2% | 7.1% | 7.2% | 7.2% | 7.1% | 6.9% | 7.3% | 6.0% | 6.6% | 6.1% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.